Company: NYXH
Filing Date: 2025-11-14
Form Type: 6-K
Source: 0001104659-25-111616
Chunk: 2

Company: Nyxoah SA
Filing Date: 2025-11-14
Form: 6-K
Chunk 2
---
 such term
is defined in Rule 501(a)) or “qualified institutional buyer” (as such term is defined in Rule 144A) under the Securities
Act.

The information included under the heading “Private Placement” of this report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers333-285960,333-261233and333-269410) and Form F-3 (Registration Numbers333-285982 and333-268955) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Registered Direct Offering

On November 13, 2025, Nyxoah SA (the
“Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors
(the “RDO Investors”), including certain institutional investors, pursuant to which the Company agreed to issue and
sell, in a registered direct offering by the Company directly to the RDO Investors (the “Registered Direct Offering”)
Ordinary Shares to the Investors, at a price of U.S.$4.6304 per share, for aggregate gross proceeds to the Company of approximately
U.S.$5.6 million before deducting related offering expenses.

The Ordinary Shares were offered by the Company
pursuant to a Registration Statement on Form S-3 (File No. 333-268955, which was filed with the Securities and Exchange Commission (the
“Commission”) on December 22, 2022 and was declared effective by the Commission on January 6, 2023 (the “Registration
Statement”).

The Company intends to use the proceeds of this Registered Direct Offering(i) to launch commercialization activities in the United
States and advance the commercialization of the Genio system in its initial target markets outside the United States; (ii) to continue
gathering clinical data and to support physician-initiated clinical research projects related to OSA patient treatments; (iii) to further
finance research and development activities related to Genio system upgrades, re-designing our products for manufacturability and cost
reduction initiatives; (iv) to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the
field of monitoring and diagnostics for OSA; and (v) for other general corporate purposes, including, but not limited to, working capital,